Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRN NASDAQ:CRVO NASDAQ:FDMT NASDAQ:TNXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$15.04-2.3%$15.64$7.08▼$17.49$318.62M0.8466,024 shs54,996 shsCRVOCervoMed$9.62+3.2%$8.16$1.80▼$20.63$86.24M-0.79148,863 shs117,713 shsFDMT4D Molecular Therapeutics$6.16-0.3%$5.15$2.23▼$17.41$288.62M2.832.54 million shs342,572 shsTNXPTonix Pharmaceuticals$29.63-3.8%$41.25$6.76▼$130.00$259.73M1.72.00 million shs667,083 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin-2.34%-5.88%+0.47%+29.66%+22.40%CRVOCervoMed+3.22%+5.37%+13.18%+35.30%-40.95%FDMT4D Molecular Therapeutics-0.32%-13.12%+39.68%+70.64%-59.74%TNXPTonix Pharmaceuticals-3.83%-21.99%-23.28%-25.55%-1.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMRNAmarin0.2699 of 5 stars0.82.00.00.02.50.00.6CRVOCervoMed2.0672 of 5 stars3.42.00.00.01.71.70.6FDMT4D Molecular Therapeutics2.2817 of 5 stars3.32.00.00.02.71.70.6TNXPTonix Pharmaceuticals2.9555 of 5 stars3.52.00.00.02.83.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 1.50Reduce$12.00-20.21% DownsideCRVOCervoMed 2.78Moderate Buy$23.71146.51% UpsideFDMT4D Molecular Therapeutics 2.64Moderate Buy$30.40393.51% UpsideTNXPTonix Pharmaceuticals 3.00Buy$70.00136.25% UpsideCurrent Analyst Ratings BreakdownLatest CRVO, TNXP, FDMT, and AMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025AMRNAmarinZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/18/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $31.008/14/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)8/12/2025CRVOCervoMedRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $16.008/12/2025FDMT4D Molecular TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$44.00 ➝ $38.008/12/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.008/11/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $15.008/11/2025CRVOCervoMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.008/1/2025FDMT4D Molecular TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.007/29/2025CRVOCervoMedCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $27.007/29/2025FDMT4D Molecular TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$228.61M1.36N/AN/A$22.48 per share0.67CRVOCervoMed$9.74M9.14N/AN/A$3.61 per share2.66FDMT4D Molecular Therapeutics$40K7,191.80N/AN/A$9.01 per share0.68TNXPTonix Pharmaceuticals$9.83M26.42N/AN/A$19.17 per share1.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$82.18M-$3.67N/AN/AN/A-47.22%-21.18%-15.00%10/29/2025 (Estimated)CRVOCervoMed-$16.29M-$2.61N/AN/AN/A-290.72%-59.15%-53.64%11/11/2025 (Estimated)FDMT4D Molecular Therapeutics-$160.87M-$3.53N/AN/AN/A-594,375.81%-40.15%-36.43%11/12/2025 (Estimated)TNXPTonix Pharmaceuticals-$130.04M-$39.47N/AN/AN/A-828.22%-57.93%-51.04%11/11/2025 (Estimated)Latest CRVO, TNXP, FDMT, and AMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025FDMT4D Molecular Therapeutics-$0.88-$0.98-$0.10-$0.98$0.52 million$0.01 million8/11/2025Q1 2025TNXPTonix Pharmaceuticals-$3.10-$3.86-$0.76-$3.86$2.60 million$2.00 million8/8/2025Q2 2025CRVOCervoMed-$0.57-$0.70-$0.13-$0.70$1.45 million$1.76 million7/30/2025Q2 2025AMRNAmarin-$0.66-$0.03+$0.63-$0.03$45.45 million$72.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/ACRVOCervoMedN/AN/AN/AN/AN/AFDMT4D Molecular TherapeuticsN/AN/AN/AN/AN/ATNXPTonix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.262.34CRVOCervoMedN/A8.208.20FDMT4D Molecular TherapeuticsN/A8.758.75TNXPTonix PharmaceuticalsN/A7.537.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%CRVOCervoMed25.15%FDMT4D Molecular Therapeutics99.27%TNXPTonix Pharmaceuticals82.26%Insider OwnershipCompanyInsider OwnershipAMRNAmarin3.30%CRVOCervoMed35.40%FDMT4D Molecular Therapeutics9.60%TNXPTonix Pharmaceuticals0.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.68 million20.02 millionOptionableCRVOCervoMed49.25 million5.98 millionNot OptionableFDMT4D Molecular Therapeutics12046.70 million42.22 millionOptionableTNXPTonix Pharmaceuticals508.77 million8.76 millionNot OptionableCRVO, TNXP, FDMT, and AMRN HeadlinesRecent News About These CompaniesTonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025August 28 at 7:00 AM | globenewswire.comTonix Pharmaceuticals (NASDAQ:TNXP) Shares Cross Above 200-Day Moving Average - Time to Sell?August 28 at 3:33 AM | marketbeat.comCarolyn Taylor Buys 418 Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) StockAugust 22, 2025 | insidertrades.comSA analyst upgrades/downgrades: HD, AAPL, TMUS, TNXPAugust 20, 2025 | msn.comTonix Pharma Announces FDA Approval of TonmyaAugust 19, 2025 | msn.comTonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)August 19, 2025 | seekingalpha.comTonix Pharmaceuticals Reports Q2 2025 Financial ResultsAugust 19, 2025 | msn.comFDA Approves New Fibromyalgia Drug, But Tonix Shares SlideAugust 18, 2025 | msn.comTonix Pharma's Drug Gets FDA Nod For Chronic Pain Condition, First New Therapy In Over 15 YearsAugust 18, 2025 | finance.yahoo.comTonix Pharmaceuticals (TNXP) Faces Volatility Despite FDA ApprovalAugust 18, 2025 | gurufocus.comFDA Approves New Fibromyalgia Drug, Tonix Shares ClimbAugust 18, 2025 | msn.comThis Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’August 18, 2025 | msn.comTonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Stock Holdings Reduced by Virtu Financial LLCAugust 18, 2025 | marketbeat.comNoble Financial Has Pessimistic Outlook of TNXP Q3 EarningsAugust 17, 2025 | marketbeat.comFDA approves first new fibromyalgia treatment in over 15 yearsAugust 16, 2025 | thepharmaletter.comTTonix Pharmaceuticals (NASDAQ:TNXP) Shares Gap Up - Time to Buy?August 16, 2025 | marketbeat.comTonix Secures Fibromyalgia Approval - What Investors Should KnowAugust 16, 2025 | seekingalpha.comTonix Pharma Gains FDA Approval for TonmyaAugust 16, 2025 | msn.comTonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of FibromyalgiaAugust 15, 2025 | manilatimes.netMTonix Pharmaceuticals jumps 17% to $60.13 after FDA approval of TonmyaAugust 15, 2025 | msn.comTonix Pharmaceuticals stock halted ahead of FDA approval newsAugust 15, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRVO, TNXP, FDMT, and AMRN Company DescriptionsAmarin NASDAQ:AMRN$15.04 -0.36 (-2.34%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$15.00 -0.04 (-0.27%) As of 08/29/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.CervoMed NASDAQ:CRVO$9.62 +0.30 (+3.22%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$9.70 +0.08 (+0.78%) As of 08/29/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.4D Molecular Therapeutics NASDAQ:FDMT$6.16 -0.02 (-0.32%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$6.25 +0.09 (+1.46%) As of 08/29/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.Tonix Pharmaceuticals NASDAQ:TNXP$29.63 -1.18 (-3.83%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$29.28 -0.36 (-1.20%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
